Helius Medical Technologies to Report Results from Traumatic Brain Injury Clinical Trials

Helius Medical Technologies to Report Results from Traumatic Brain Injury Clinical Trials

Webcast to be held Thursday, November 9th, 8:00 AM ET

NEWTOWN, Pa., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (TSX:HSM), (OTCQB:HSDT) ("Helius" or the "Company"), a medical technology company focused on neurological wellness, announced today that it will report the results of its registrational trial investigating the safety and effectiveness of the Portable Neuromodulation Stimulator (PoNStm) for the treatment of chronic balance deficits due to mild-to-moderate Traumatic Brain Injury (TBI) by press release to be issued on Thursday, November 9, 2017 at 6:00 AM ET. The Company also plans to report results from a long-term clinical trial of the PoNS Therapy for the treatment of symptoms due to mild- to moderate TBI, performed at the University of Wisconsin-Madison.

Philippe Deschamps, the president and chief executive officer of Helius, will provide a presentation of the data, along with a company update, on Thursday, November 9, 2017 at 8:00 AM ET via webcast at http://www.wsw.com/webcast/cc/hsdt. Interested parties may also listen to the presentation by calling 1 (866) 939-3921 (US Toll Free) or 1 (678) 302-3550 (US Toll). Please use confirmation number 45986789. An archived copy of the webcast will be available at www.heliusmedical.com and http://www.wsw.com/webcast/cc/hsdt .

About PoNStm Therapy

The Portable Neuromodulation Stimulator (PoNStm) is an investigational non-invasive device designed to deliver neurostimulation through the tongue.  PoNStm Therapy combines the use of the device with physical therapy and is currently being evaluated in a multicenter clinical trial for the treatment of balance disorder for subjects with mild to moderate traumatic brain injury.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a medical technology company focused on neurological wellness. Helius seeks to develop, license and acquire unique and non-invasive platform technologies that amplify the brain's ability to heal itself.  Helius intends to file for FDA clearance for the PoNStm device.  For more information, please visit www.heliusmedical.com. 

The Toronto Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

HELIUS CONTACTS:

Investor Relations: 
Josh Berg, 415-205-7891
[email protected]

Media Contact:
Becky Kern, 914-772-2310
[email protected]